The Journal of Pediatrics of Korean Medicine (대한한방소아과학회지)

The Association of Korean Oriental Pediatrics (대한한방소아과학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Bangpungtongsungsan on Insulin Resistance Induced by Non-alcoholic Fatty Liver Disease (NAFLD)

방풍통성산의 지방대사조절을 통한 비알콜성 지방간 유도 인슐린저항성 개선 효과

  • Seo, Il-bok (Department of Anatomy, College of Korean Medicine, Semyung University) ;
  • Ahn, Sang Hyun (Department of Anatomy, College of Korean Medicine, Semyung University) ;
  • Kim, Ki Bong (Department of Korean Pediatrics, Korean Medicine Hospital, Pusan National University)
  • 서일복 (세명대학교 한의과대학 해부학교실) ;
  • 안상현 (세명대학교 한의과대학 해부학교실) ;
  • 김기봉 (부산대학교한방병원 한방소아과)
  • Received : 2018.10.15
  • Accepted : 2018.11.13
  • Published : 2018.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives Bangpungtongsungsan is an herbal medicine that treats obesity and dampness-phlegm. The aim of this study was to investigate the efficacy of Bangpungtongsungsan on insulin resistance induced by non-alcoholic fatty liver disease. Methods Male 6-week-old C57BL/6 male mice were divided into four groups: control group (Ctrl), high fat diet group (HFF), high fat diet with Bangpungtongsungsan extract administration group (BT1), and high fat diet with double concentration of Bangpungtongsungsan extract administration group (BT2). Each 10 mice were allocated to each group (total of 40 mice). All mice were allowed to eat fat rich diet freely throughout the experiment. To examine the effect of Bangpungtongsungsan, we observed weight changes, lipid blot distributions, PGC-1, $p-I{\kappa}B$, 8-OHdG, p-JNK, total cholesterol and glucose levels. Results Comparing of body weight measurements between 4 groups, weight gain was significantly lower in BT1 and BT2 group than the HFF group. The distribution of lipid blots and positive reaction of PGC-1 were significantly lower in BT1 and BT2 group. The positive reaction of $p-I{\kappa}B$ and 8-OHdG in hepatic tissues was significantly lower in BT1 and BT2 group. The positive reaction of p-JNK in hepatic tissues was significantly lower in BT1 and BT2 group. Total cholesterol and glucose levels were significantly lower in BT1 and BT2 group. Conclusions Bangpungtongsungsan has the effect of improving non-alcoholic fatty liver induced insulin resistance through regulation of lipid metabolism.

Keywords

HHSSB3_2018_v32n4_1_f0001.png 이미지

Fig. 1. The mitigative effects of Bangpungtongsungsan in hepatic tissue of mice with non-alcoholic fatty liver disease (NAFLD)

HHSSB3_2018_v32n4_1_f0002.png 이미지

Fig. 2. The regulation of lipogenesis in hepatic tissue of mice with NAFLD by Bangpungtongsungsan

HHSSB3_2018_v32n4_1_f0003.png 이미지

Fig. 3. The decrease of hepatic stress and anti-inflammation in hepatic tissue of mice with NAFLD by Bangpungtongsungsan (p-IκB and 8-OHdG immunohistochemistry)

HHSSB3_2018_v32n4_1_f0004.png 이미지

Fig. 4. The alleviation of insulin resistance in hepatic tissue of mice with NAFLD by Bangpungtongsungsan (p-JNK immunohistochemistry)

HHSSB3_2018_v32n4_1_f0005.png 이미지

Fig. 5. The decrease of total cholesterol & glucose in blood by Bangpungtongsungsan

HHSSB3_2018_v32n4_1_f0006.png 이미지

Fig. 6. No side effect in hepatic tissue of mice by Bangpungtongsungsan administration

Table 1. The Amount and Composition of Bangpungtongsungsan Extract

HHSSB3_2018_v32n4_1_t0001.png 이미지

Table 2. Effects of Bangpungtongsungsan on Body Weight in High Fat Diet Feeding Mice

HHSSB3_2018_v32n4_1_t0002.png 이미지

References

  1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5-10.
  2. Korea Food & Drug Administration. The press release [Internet]. [Retrieved Nov. 14, 2013]. Available from: http://www.mfds.go.kr/index.do?mid=675&seq=19618&cmd=v
  3. Oh K, Jang MJ, Lee NY, Moon JS, Lee CG, Yoo MH, Kim YT. Prevalence and trends in obesity among Korean children and adolescents in 1997 and 2005. Korean J Pediatr. 2008;51(9):950-5. https://doi.org/10.3345/kjp.2008.51.9.950
  4. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61. https://doi.org/10.1159/000282080
  5. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28(1):13-24. https://doi.org/10.1111/j.1365-2036.2008.03703.x
  6. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80. https://doi.org/10.1002/hep.1840110114
  7. Ahn YJ, Yoon KH, Jo JH, Jang DH, Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon M, Shin SS. Gangjihwan improves nonalcoholic fatty liver disease in high fat diet-fed C57BL/6N mice. Kor J Herbology. 2014;29(2):47-54. https://doi.org/10.6116/KJH.2014.29.2.47
  8. Lee BW. Management of patients with nonalcoholic fatty liver disease with lifestyle modification. Korean Diabetes. 2018;19:82-7. https://doi.org/10.4093/jkd.2018.19.2.82
  9. Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother. 2010;44(10):1655-9. https://doi.org/10.1345/aph.1P099
  10. Peterfy M, Phan J, Xu P, Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet. 2001; 27(1):121-4. https://doi.org/10.1038/83685
  11. Xu J, Lee WN, Phan J, Saad MF, Reue K, Kurland IJ. Lipin deficiency impairs diurnal metabolic fuel switching. Diabetes. 2006;55(12):3429-38. https://doi.org/10.2337/db06-0260
  12. Yao-Borengasser A, Rasouli N, Varma V, Miles LM, Phanavanh B, Starks TN, Phan J, Spencer HJ, McGehee RE, Reue K, Kern PA. Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation. Diabetes. 2006;55(10):2811-8. https://doi.org/10.2337/db05-1688
  13. Hong JY. Effects of Bangpungtongseungsan and Monacolin K. on body weight, food consumption, serum and expression of ${\beta}3AR$ in high fat mice. Wonkwang University Doctor's Thesis. 2009.
  14. Choi EM, Ryu EK. Effects of Fangfengtongsheng-san on obese patients. J Soc Korean Med Obes Res. 2001; 1(1):57-62.
  15. Ahn JM, Kim SS, Shin HD. Effects of Bangpoongtongsungsan on the weight and lipid metabolism of induced obesity rats. J Kyung Hee Univ Med Cent. 1993;9(1):69-82.
  16. Hwang SJ, Song TW, Oh MS. The inhibitory effects of Bangpungtongseoung-san on the obese gene and obese inhibitory about obese-mouse induced by high fat diet. J Korean Orient Med. 2006;27(1):11-22.
  17. Shin BC, Song YS. Effects of Bangpungtongseoungsan on rats with adipocyte induced by gold thioglucose. J Korean Med Rehabil. 1997;7(1):101-19.
  18. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 2003;26(12):3351-2.
  19. Jang YS, Seo JY, kwun MJ, Kwon JN, Lee I, Hong JW, Kim SY, Choi JY, Park SH, Joo M, Han CW. Effect of Phaseolus angularis seed on experimental cellular model of nonalcoholic fatty liver disease. Korean J Orient Physiol Pathol. 2013;27(6):802-8.
  20. Kim SY, Kwon JN, Lee I, Hong JW, Choi JY, Park SH, Kwon MJ, Joo M, Han CW. Research on anti-lipogenic effect and underlying mechanism of Laminaria japonica on experimental cellular model of non-alcoholic fatty liver disease. J Int Korean Med. 2014;35(2):175-83.
  21. Han CW, Lee JH. Effects of KHchunggan-tang on the nonalcoholic fatty liver disease in palmitate-induced cellular model. J Korean Orient Med. 2011;32(1):109-20.
  22. Kim K, Ko H, Shin S. Diagnostic process analysis of prescribing Injinho-tang in non alcohoic fatty liver disease using by AHP. J Soc Korean Med Diagn. 2015; 19(3):159-71.
  23. Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon KH, Jo JH, Jang DH, Yun HY, Yoon M, Shin SS. Comparison of Gangjihwan-1,2,3,4 and combination of Gangjihwan-1 and Gamisochehwan in the improvement effects of nonalcoholic fatty liver disease in a high fat diet-fed obese mouse model. Kor J Herbology. 2014;29(6):149-56. https://doi.org/10.6116/KJH.2014.29.6.149.
  24. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95. https://doi.org/10.1002/hep.20466
  25. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129(1):375-8. https://doi.org/10.1053/j.gastro.2005.05.041
  26. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73. https://doi.org/10.1002/hep.21327
  27. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-6. https://doi.org/10.1002/hep.20410
  28. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-21. https://doi.org/10.1053/j.gastro.2005.04.014
  29. Son CK. The research of immunological function in liver. J Korean Orient Med. 2001;22(1):3-9.
  30. Lee SM, Kim BW, Kwon KR, Rhim TJ, Kim DH. The effect of Bangpungtongsung-san extracts on adipocyte metabolism. J Pharmacopuncture. 2008;11(1):163-76. https://doi.org/10.3831/KPI.2008.11.1.163
  31. Jeong SH, Lee KT, Ann HS, Lee JY, Choi JW, Kim DG. Hypolipidemic and antioxidative effects of Bangpoongtongsungsankamibang on diet-induced obesity rats. 2006;37(3):190-5.
  32. Lee JC. Effects of Gamibangpungtongseungsan on lipid composition and antioxidant in rat fed high fat. Kor J Herbology. 2005;20(2):69-75.
  33. Lee NH, Shin GJ, Cho KH, Kim S, Bae HS, Lee KS. Effect of Bangpoorgtonsungsan on the hypertention and hyperlipidemia. J Kyung Hee Univ Med Cent. 1991; 22(1):101-9.
  34. Yun KY. Donguiimsangbangjehag. Seoul: Myungbo Publishing Co. 1992:52-4.
  35. Hwang DY. Bangyakhappyeon. Seoul: Namsandang. 1987:122.
  36. Park MJ, Kim DI, Lim SK, Choi JH, Kim JC, Yoon KC, Lee JB, Lee JH, Han HJ, Choi IP, Kim HC, Park SH. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-$1{\alpha}$ regulation in vitro and in vivo. J Hepatol. 2014;61(5): 1151-7. https://doi.org/10.1016/j.jhep.2014.06.032
  37. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366-74. https://doi.org/10.1002/hep.21655
  38. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40(1):185-94. https://doi.org/10.1002/hep.20283
  39. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28(4):370-9. https://doi.org/10.1055/s-0028-1091981
  40. Kim TH. Obesity and fatty liver disease. Korean J Med. 2005;68(4):347-50.
  41. Baeuerle PA, Baltimore D. NF-${\kappa}B$: ten years after. Cell. 1996;87(1):13-20. https://doi.org/10.1016/S0092-8674(00)81318-5
  42. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115-7. https://doi.org/10.1096/fj.03-0329fje
  43. Cha HY, Ahn SH, Cheon JH, Park IS, Kim JT, Kim KB. Hataedock treatment has preventive therapeutic effects in atopic dermatitis-induced NC/Nga mice under high-fat diet conditions. Evid Based Complement Alternat Med. 2016;2016:1-13.
  44. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634-43. https://doi.org/10.1001/jama.298.22.2634
  45. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-8. https://doi.org/10.1001/jama.298.10.1180